Jardiance Cost in Alabama 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Alabama in 2026?

The cash-pay price for a 30-tablet supply of Jardiance (empagliflozin 10 mg or 25 mg) at Alabama retail pharmacies sits at approximately $680 per month in 2026. That figure reflects the Boehringer Ingelheim/Lilly manufacturer list price and has not materially changed from 2025. Without insurance or a savings program, patients at CVS, Walgreens, Walmart, and independent Alabama pharmacies will be quoted within a few dollars of that number.

GoodRx and similar aggregators rarely discount Jardiance below $620 at in-state chains because empagliflozin has no FDA-approved generic equivalent as of mid-2025. The FDA has not yet granted tentative approval to any ANDA filer for empagliflozin tablets, so the branded market holds [1]. The Hatch-Waxman exclusivity period has kept biosimilar and generic entry at bay, and analysts tracking the drug do not expect a generic before 2029 at the earliest.

For context, the EMPA-REG OUTCOME trial, which enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease, demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin 10 mg or 25 mg versus placebo over a median of 3.1 years (hazard ratio 0.62; 95% CI 0.49-0.77; P<0.001) [2]. Those outcomes data are why cardiologists and endocrinologists continue to prescribe a drug that costs nearly $700 per month.

The EMPEROR-Reduced trial (N=3,730) extended those findings to heart failure with reduced ejection fraction, showing a 25% relative risk reduction in the composite of CV death or worsening heart failure (HR 0.75; 95% CI 0.65-0.86; P<0.001) [3]. The EMPEROR-Preserved trial then confirmed benefit in heart failure with preserved ejection fraction, the first drug to do so [4]. These back-to-back trial results mean Alabama physicians across cardiology, nephrology, and primary care are writing Jardiance scripts at high volume, making cost navigation a daily practical problem for Alabama patients.

Separately, the EMPA-KIDNEY trial (N=6,609) showed empagliflozin reduced the risk of kidney disease progression or CV death by 28% versus placebo (HR 0.72; 95% CI 0.64-0.82; P<0.001), leading to the expanded CKD label [5].

Does Alabama Medicaid Cover Jardiance?

Alabama Medicaid does not cover Jardiance (empagliflozin) as of 2026 for most covered populations. The Alabama Medicaid Agency's preferred drug list (PDL) places SGLT2 inhibitors in a non-preferred tier for most formulary categories, and prior authorization for empagliflozin is rarely approved outside narrow exceptions [6].

This is a meaningful gap. Alabama has one of the highest rates of type 2 diabetes in the United States, with the CDC reporting that approximately 13.4% of Alabama adults carry a diabetes diagnosis [7]. A large share of those patients are Medicaid-enrolled, yet the drug with the strongest cardiovascular outcomes data in its class sits outside routine coverage.

Patients who believe they meet criteria for a medical exception can request prior authorization through their Alabama Medicaid managed care organization. The approval rate for SGLT2 inhibitor PA requests varies by plan. Patients with documented heart failure (NYHA Class II-IV) or stage 3-4 CKD with albuminuria have the strongest clinical argument for an exception, given the FDA label expansions triggered by EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY [3][4][5].

Alabama does not currently operate a state pharmaceutical assistance program (SPAP) that supplements Medicaid gaps for Jardiance. Patients on Medicare Part D face a separate formulary structure; see the section on insurance below.

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established CVD, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events" [8]. That guideline language is useful documentation when appealing a Medicaid denial in Alabama.

Which Insurance Plans Cover Jardiance in Alabama and What Do You Pay?

Most commercial insurance plans available through Alabama employers and the federal Marketplace cover Jardiance, but tier placement and cost-sharing vary considerably. Tier 2 placement is common; tier 3 is also frequent. Copays range from $45 to $150 per month depending on plan design and deductible status.

Medicare Part D coverage depends on the specific plan. As of 2026, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D beneficiaries limits maximum annual exposure, but monthly cost-sharing before hitting that cap can still be substantial. The Social Security Administration and CMS have finalized the $2,000 cap for 2025 plan year forward [9].

BCBS of Alabama, United Healthcare, Aetna, and Cigna all offer plans in the Alabama Marketplace that include empagliflozin on formulary. Tier placement and copay amounts change annually with each plan's formulary update. Patients should run a formulary check on their insurer's website or call member services before assuming coverage applies to the current plan year.

For Medicare Advantage plans sold in Alabama, the formulary is plan-specific. CMS requires MA-PD plans to cover at least two drugs per class per category, but SGLT2 inhibitors occupy a pharmacological class where plan sponsors retain tier and PA discretion. Patients whose plan places Jardiance on a specialty tier may face 25-33% coinsurance before the annual cap, which can mean $150-$225 per month during the deductible phase [9].

The FDA-approved prescribing information for empagliflozin confirms the approved doses (10 mg and 25 mg for type 2 diabetes; 10 mg for heart failure and CKD) [1], and insurance PA criteria often mirror the label indications exactly.

How the Boehringer Ingelheim/Lilly Savings Card Works in Alabama

The Jardiance savings card, offered jointly by Boehringer Ingelheim and Eli Lilly, is available to commercially insured patients in Alabama who are not enrolled in a federal or state government insurance program (Medicaid, Medicare, TRICARE, or VA). Eligible patients can pay as little as $10 per month for a 30-day supply.

The card is downloaded or printed from the Jardiance manufacturer website, presented at any participating Alabama pharmacy, and applied at the point of sale. There is no income threshold for commercial patients; the primary eligibility requirement is non-government insurance. The card covers up to $150 per fill in copay relief, with an annual maximum that resets each calendar year.

Patients who are uninsured are not eligible for the commercial savings card but may apply for the Boehringer Ingelheim Cares Foundation patient assistance program (PAP), which provides free medication to qualifying low-income patients. Income thresholds are set at approximately 400% of the federal poverty level, and Alabama residents can apply via the manufacturer's PAP portal with documentation of income and a prescriber's attestation.

The savings card does not work at pharmacy benefit managers that require a separate adjudication process (some employer plans with a PBM carve-out). In those cases, the patient may need to use the card as a secondary adjudication or switch to a participating retail pharmacy.

Is Compounded Empagliflozin Legal in Alabama?

Compounded empagliflozin is legal in Alabama when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Alabama follows federal 503A rules under the Drug Quality and Security Act (DQSA), which require a licensed prescriber to issue a non-commercially-available or medically-necessary formulation for a specific patient [10].

The key legal question for SGLT2 inhibitors specifically is whether the FDA considers empagliflozin a "difficult to compound" substance or places it on a list that restricts 503A compounding. As of mid-2025, empagliflozin is not on the FDA's 503A bulk drug substances list of prohibited substances, meaning compounding remains permissible under current federal guidance. However, FDA policy in this area has shifted for other drug classes, and prescribers and patients should verify current status before initiating a compounded prescription [10].

503A pharmacies in Alabama must hold a valid Alabama Board of Pharmacy license. The pharmacy must prepare the compound pursuant to a valid prescription, for an individual identified patient, and in compliance with USP <795> standards for non-sterile compounding. The compounded product cannot be sold wholesale or in anticipation of prescriptions (that model falls under 503B outsourcing facilities, which face different federal requirements).

Cost for compounded empagliflozin varies by pharmacy. Some Alabama telehealth platforms partner with licensed 503A pharmacies and offer compounded empagliflozin at significantly lower monthly costs than the branded product. Patients should ask the pharmacy for the Certificate of Analysis (CoA) for each batch, confirming active pharmaceutical ingredient (API) identity, purity, and potency before taking any compounded preparation.

The HealthRX clinical team uses the following decision framework when counseling Alabama patients on branded versus compounded empagliflozin:

1. Commercially insured with savings card eligibility: use branded Jardiance at $10/month via savings card.
2. Alabama Medicaid only: file PA with CKD or HF documentation; if denied, evaluate 503A compounded option or PAP.
3. Uninsured with income <400% FPL: apply for Boehringer Ingelheim Cares PAP for free branded drug.
4. Uninsured with income >400% FPL: 503A compounded empagliflozin from a licensed Alabama pharmacy with verified CoA is a reasonable option.
5. Medicare Part D: apply IRA $2,000 annual OOP cap; escalate to Low Income Subsidy (Extra Help) if eligible.

Can You Get Jardiance via Telehealth in Alabama?

Telehealth prescribing of Jardiance is legal in Alabama. Alabama lifted its pandemic-era telehealth restrictions and codified audio-video prescribing authority for Schedule III-V controlled substances and non-controlled medications through the Alabama Telehealth Act (Act 2021-436). Empagliflozin is a non-controlled oral medication, so a licensed Alabama prescriber can issue a valid prescription after a synchronous telehealth visit without an in-person exam [11].

The prescriber must hold an active Alabama medical license or, for out-of-state telehealth providers, must register with the Alabama Board of Medical Examiners under the Interstate Medical Licensure Compact (IMLC) if applicable. The prescribing standards (history, examination sufficient to establish a diagnosis, informed consent) apply equally to telehealth and in-person visits.

Alabama telehealth visits for empagliflozin typically include a review of A1C, eGFR, urine albumin-to-creatinine ratio (UACR), blood pressure, and current medications. The FDA label contraindicates empagliflozin in patients with eGFR <20 mL/min/1.73 m2 for the diabetes indication and notes reduced glycemic efficacy below eGFR 45 [1]. A prescriber conducting a telehealth visit will request recent lab work before prescribing or writing a lab order concurrent with the visit.

Multiple national telehealth platforms operate in Alabama and can connect patients with a licensed prescriber within 24-48 hours. HealthRX providers follow the ADA 2024 Standards of Care and the 2023 ACC Expert Consensus Decision Pathway when evaluating SGLT2 inhibitor candidacy [8][12].

What Are the Clinical Reasons Alabama Physicians Prescribe Empagliflozin?

Empagliflozin carries FDA approval for three distinct indications, each supported by a separate landmark trial program. Type 2 diabetes glycemic control was the original 2014 approval. Cardiovascular risk reduction in adults with type 2 diabetes and established CVD followed the EMPA-REG OUTCOME data [2]. Heart failure (both reduced and preserved ejection fraction) was approved after EMPEROR-Reduced and EMPEROR-Preserved [3][4]. Chronic kidney disease risk reduction followed EMPA-KIDNEY [5].

The standard starting dose for type 2 diabetes is 10 mg once daily in the morning, with or without food. The dose may be increased to 25 mg once daily for additional glycemic control if tolerated and eGFR permits. For heart failure and CKD indications, the approved dose is 10 mg once daily regardless of glycemic goals [1].

Common adverse effects include genital mycotic infections (occurring in roughly 6-8% of women and 3-4% of men in EMPA-REG OUTCOME), urinary tract infections, and polyuria from the glucosuric mechanism. Rare but serious risks include diabetic ketoacidosis (DKA), Fournier's gangrene, and lower limb amputations at rates that differ by SGLT2 inhibitor; empagliflozin's amputation signal was lower than canagliflozin's in head-to-head analyses [13].

The ACC 2023 Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment recommends initiating an SGLT2 inhibitor in all patients with HFrEF and HFpEF who can tolerate it, independent of diabetes status: "SGLT2 inhibitors are recommended for patients with HFrEF to reduce the risk of worsening HF and CV death regardless of the presence of type 2 diabetes" [12].

Renal protective effects are mediated partly through hemodynamic mechanisms (reduction in intraglomerular pressure) rather than solely through glucose lowering, which is why empagliflozin benefits patients without diabetes in EMPA-KIDNEY, where 54% of participants did not have type 2 diabetes [5].

Practical Steps for Alabama Patients to Reduce Their Jardiance Cost Right Now

Getting from $680 to a manageable monthly cost requires knowing which program applies to your situation. These steps are ordered from highest-savings to lowest-savings for most Alabama patients.

Step 1: Check your commercial insurance formulary. Log into your insurer's member portal and search "empagliflozin" or "Jardiance." Note the tier and any PA requirement. If PA is required, your prescriber's office can submit documentation of your diagnosis and qualifying trial or guideline language.

Step 2: Stack the savings card on top of commercial insurance. If you have commercial insurance (not Medicaid or Medicare), download the Boehringer Ingelheim/Lilly savings card. Present both your insurance card and the savings card at the pharmacy. Most Alabama retail pharmacies process this automatically.

Step 3: Apply for PAP if uninsured and income-eligible. The Boehringer Ingelheim Cares Foundation provides branded Jardiance at no cost to qualifying patients. Your prescriber submits a PAP application with your income documentation.

Step 4: Evaluate compounded empagliflozin if none of the above applies. Ask your telehealth or primary care prescriber whether a 503A-compounded empagliflozin preparation is clinically appropriate. Request the pharmacy's CoA for the batch you receive. Confirm the pharmacy's Alabama Board of Pharmacy license number before dispensing.

Step 5: Appeal Alabama Medicaid denials with trial data. If you are on Medicaid and your PA was denied, submit a formal appeal citing EMPA-REG OUTCOME [2], EMPEROR-Reduced [3], or EMPA-KIDNEY [5] alongside ADA 2024 guideline language [8]. Attach your most recent eGFR and UACR labs. Appeals with objective clinical documentation have a higher approval rate than initial PA submissions.

The ADA 2024 Standards of Care set an A1C target of <7.0% for most non-pregnant adults with type 2 diabetes and recommend SGLT2 inhibitors as preferred add-on agents when cardiorenal risk is present, irrespective of baseline A1C [8]. Alabama patients who qualify clinically should not forgo a drug with that level of evidence because of cost alone; at least one of the programs above applies to the vast majority of patients.